8-K: OSR Health Faces Nasdaq Delisting, Plans Appeal

OSR Health, Inc. has received a delisting determination from Nasdaq due to failure to meet minimum bid price requirements and intends to request a hearing.

Summary

• OSR Health, Inc. received a Staff Delisting Determination from Nasdaq on August 19, 2026, indicating its common stock and warrants will be delisted from the Nasdaq Capital Market.
• The delisting is due to non-compliance with Nasdaq Listing Rule 5550(a)(2), requiring a minimum closing bid price of $1.00 per share.
• Trading suspension is scheduled for the opening of business on August 26, 2026.
• The company intends to request a hearing before a Nasdaq Hearings Panel to appeal the determination.
• A timely hearing request will stay the filing of Form 25-NSE (delisting document) pending the Panel's decision, but will not stay the trading suspension.
• The company highlights significant trading volume on August 17 and 18, 2026, with its share price reaching an intraday high of $0.84 on August 18, just $0.16 below the compliance threshold.
• The company believes its trading history, recent market activity, and underlying business fundamentals present a compelling case for continued listing.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a negative development due to the impending delisting from Nasdaq, despite the company's intent to appeal.

Positives

• The company intends to appeal the delisting determination, indicating a proactive stance to retain its Nasdaq listing.
• Significant trading volume on August 17 and 18, 2026, with 370 million and 145 million shares traded respectively, suggests strong investor interest.
• The share price reached an intraday high of $0.84 on August 18, demonstrating a close proximity to the $1.00 compliance threshold.
• The company believes it has a compelling case to present to the Nasdaq Hearings Panel based on its trading history, recent market activity, and business fundamentals.

Negatives

• The company has received a Staff Delisting Determination from Nasdaq, indicating a failure to meet continued listing requirements.
• Trading of the company's common stock and warrants is scheduled to be suspended at the opening of business on August 26, 2026.
• The company was not in compliance with the minimum closing bid price requirement of $1.00 per share.
• Despite multiple compliance periods, the company could not regain compliance by the August 31, 2026 deadline.
• A timely hearing request will not stay the scheduled suspension of trading, meaning trading will cease on August 26, 2026, regardless of the appeal outcome.

Risks

• Failure to regain compliance with Nasdaq's minimum bid price requirement could lead to permanent delisting.
• The trading suspension on August 26, 2026, will significantly impact liquidity and investor access to the company's securities.
• There is no assurance that the Nasdaq Hearings Panel will grant the company's request for continued listing.
• If the Panel does not grant the request, Nasdaq will file a Form 25-NSE to remove the securities from listing and registration.
• The company's ability to access capital markets may be severely hampered if delisted from Nasdaq.

Future Outlook

The company is actively pursuing an appeal to continue its listing on the Nasdaq Capital Market. The outcome of the Nasdaq Hearings Panel's decision is uncertain, and there is no guarantee of continued listing or regaining compliance with Nasdaq's requirements.

Management Comments

• "The market spoke with extraordinary conviction on August 17 and 18," said Peter Hwang, Chief Executive Officer of OSR Health.
• "370 million shares traded in a single day against an 18.5 million share float. We came within sixteen cents of compliance."
• "We are requesting a Panel hearing because we believe the facts support our case, and because our shareholders, who have demonstrated their conviction in this Company so clearly, deserve nothing less than our full effort to fight for continued listing."
• "Whatever the outcome of that process, our commitment to our shareholders does not change."

Industry Context

StockSavvy.ai notes that delisting proceedings due to low bid prices are a common challenge for smaller-cap companies, especially in volatile market conditions. The company's strategy to appeal, emphasizing recent trading activity and business fundamentals, is a standard approach in such situations.

Stakeholder Impact

• Shareholders: Potential loss of liquidity and market access if delisted; uncertainty regarding the future trading of their shares.
• Employees: Potential impact on morale and stock-based compensation if the company's public trading status is jeopardized.
• Creditors: Potential concerns about the company's financial stability and ability to meet obligations if access to capital markets is restricted.

Next Steps

• Request a hearing before the Nasdaq Hearings Panel by 4:00 p.m. Eastern Time on August 26, 2026.
• Present a case to the Panel for continued listing, highlighting trading history, recent market activity, and business fundamentals.
• Await the Panel's decision regarding continued listing.
• Provide further updates to shareholders regarding the status of its securities as developments warrant.

Key Dates

Recommendation

The company is facing delisting, which is a significant negative. However, it is actively appealing the decision and has demonstrated recent high trading volume and a close proximity to the compliance threshold. The outcome of the appeal is uncertain, making a 'hold' recommendation appropriate for existing investors who can tolerate the risk, while new investment is not advised until the listing status is resolved.

Keywords

delisting, Nasdaq, bid price, hearing request, trading suspension, compliance, securities, appeal